Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits;Efeitos da atorvastatina, fluvastatina, pravastatina e simvastatina sobre a função endotelial, a peroxidação lipídica e a aterosclerose aórtica em coelhos hipercolesterolêmicos

Arquivos Brasileiros de Cardiologia

Volumn 84, Issue 4, 2005, Pages 314-319

  Jorge, Paulo Afonso Ribeiro ^a,b   De Almeida, Eros Antonio ^a   Ozaki, Michiko R ^a   Jorge, Mariana ^a   Carneiro, Adriano ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Rua Guilherme Da Silva   (Brazil)

Author keywords

Aortic atherosclerosis; HMG CoA reductase inhibitors; Lipid peroxidation

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PRAVASTATIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERY DILATATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; FEEDING; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; NONHUMAN; RABBIT;

EID: 18844440664     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0066-782X2005000400008     Document Type: Article

References (56)

1. Shepherd J, Cobbe SM et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study (WOSCOPS). N Engl J Med 1995; 333:1301-7.
2. AFCAPS/TEXCAPS, Domws JR, Clearfield M et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. N Engl J Med 1998;339:1349-57.
3. LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease-LIPID Study Group. N Engl J Med 1998;339:1349-57.
4. 4S (Scadinavian Simvastatin Survival Study Group). Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 1994;344:1383-9.
5. Sacks FM, Pfeffer MA et al. The effect of pravastatin on coronary events after myocardial infaction in patients with average cholesterol levels. Care Study N Engl J Med 1966;14:1001-9.
6. The Heart Protection Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:23-33.
7. Vaughan CJ, Gotto AM, Basson CT. The envolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
8. Ricker PM, Rifail N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hyperchoelsterolemia. Circulation 2001; 103:1191-3.
9. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L. Direct vascular effects of HMGCoA reductase inhibitors. Atherosclerosis 137:S101-S109, 1998.
10. Scalia R, Appel JZ, Lefer AM. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit. Arterioscl Thromb Vasc Biol 1998;18:1093-100.
11. Dangas GJ, Badimon L, Smith DA, Levine A, Ambrose JA. Pravastatin therapy in hyperlipidemia. Effects on thrombus formation and the systemic hemostatic profile. Am Coll Cardiol 1999; 33:1294-304.
12. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG-COA reductase inhibitors unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001;49:281-7.
13. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-370.
14. Corsini A, Maggi F, Catapano AL. Pharmacology of competitive inhibitors of HMGCoA reductase. Pharmacological Res 1995; 31:9-27.
15. Dansette PM, Joen M, Rons C. HMGCoA reductase activity in human liver microssomes: comparative inhibition by statins. Exp Tox Pathol 2000;52:145-8.
16. Jones P, Kafonek S, Laurora I, Hunninghake, Curves investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia. (The Curves Study). Am J Cardiol 1998;81:582-7.
17. Ribeiro JPA, Ozaki MK. Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits. Exp Toxic Pathol 1994; 46: 465-9.
18. Ribeiro JPA, Eros AA, Ozaki MR et al. Rapid reversal of endothelial dysfunction in hypercholeterolemic rabbits treated with sinvastatin and pravastatin. Clin Exp Pharmacol Physiol 1997; 24:948-95.
19. Cassini AF, Ferrali M, Pompella A, Maellaro E, Comporti M. Lipid peroxidation and cellular damage in extrahepatic tissue of bromobenzene- intoxicated mice. Am J Pathol 1986; 123:520-531.
20. Havel RJ, Eder HA, Bragdon J H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RL. Protein measurement with the Folin phenol reagent. J Biol Chem 1951:193:265-75.
22. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum J, Steinberg DE. Low density lipoprotein rich in oleic acid is preotected against oxidative modifications: implications for dietary prevention of atherosclerosis. Porc Natl. Acad Sci USA 1990;87:3894-8.
23. Buege, JA, Aust, SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-310.
24. Lehr HA, Mankoff DA, Corwin D. Application of Photoshop-based analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997; 45: 1559-65.
25. Lehr HA, Van der Loos CM, Teeling P. Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 1999; 47: 119-126.
26. nd ed (1981).
27. Milliken GA & Johnson DE, Analysis of Messy Data. Vol I: Designed Experiments. New York: Van Nostrand Reinhold (1984).
28. Motti C, Gnasso A, Cortese C. Statins: similarities and differences in the pharmacological, clinical and laboratory aspects. Ann Ital Med Int 2000, 15: 96-102.
29. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9-27.
30. Negre-Aminou P, van Erck M, van Leeuwen RE, Collard JG, Cohen LH. Differencial effect of simvastatin on various signal transduction intermediates in cultured human smooth muscle cells. Biochm Pharmacol 2002; 61: 991-8.
31. Davignon J, Mabile L. Mechanisms of action of statins and their pleiotropic effects. Ann Endocrinol(Paris) 2001; 62: 101-2.
32. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation and plaque stability. Cardiovasc Res 2000; 47: 648-57.
33. Takemoto M, Lia JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thrombo Vasc Biol 2001;21: 1712-9.
34. Hughes AD. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. J Hum Hypertens 1996; 10:387-90.
35. Carneado J, Alvarez de Sotomayor M, Perez-Guerrero C et al. Simvastatin improves endothelial function in spontaneiusly hypertensive rats through a superoxide dismutase mediated antioxidant effect. J Hypertens 2002, 20: 429-37.
36. Suzumura K, Tanaka K, Yasuhara M, Narita H. Inhibitory effects of fluvastastin and its metabolites on hydrogen peroxide induced oxidative destruction of hemin and low desnsity lipoprotein. Biol Pharmacol Bull 2000:23:837-78.
37. Salonen R, Nyyssonen K, Porkkala-Sarataho. The Kuopio Atherosclerosis Prevention Study: effects of pravastatin teatment on lipids, oxidation resistance of lipoproteins and atherosclerosis progression. Am J Cardiol 1995; 76: 3.
38. Wassmann S, Laufs U, Muller K et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22:300-5.
39. Laufs V, Fata Vita BA, Plutzky J, Liao K. Up regulation of endothelial nitric oxide after lipid lowering therapy in hypercholesterolemic patients. Circulation 1998; 98:211-6.
40. Pentikainen PJ, Saraheimo M, Swartz JI. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. L Clin Pharmacol 1992;32: 136-40.
41. Germershausern JI, Hunt VM, Bostedor RG. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Comm 1989; 158:667-75.
42. Endo A, Tsujita Y, Kuroda M, Tanzaka K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochem Biophys Acta 1979; 576: 266-76.
43. Thiery J, Nebendhal K, Walli AK. Effects of three different HMGCoA reductase inhibitors on hypercholesterolemia and atherosclerosis in cholesterol fed-rabbits. Arterioscler Tromb 1991; 11: 148.
44. DeVries AC, Vermeer MA, Bloemendal H, Coehn LH. Pravastatin and simvastatin differently inhibit cholesterol biossynthesis humanas lens. Invest Ophthalmol Vis Sci 1993; 34:377-84.
45. Tesfamariam B, Frohlich BH, Gregg RE. Differencial effects of pravastatin, simvastatin, and atorvastatin on Ca++ release and vascular reactivity. J Cardiovasc Pharmacol 1999; 34:95-101.
46. Joukhadar C, Klein N, Schrolnberger C, Vukovich T, Wolzt M, Dorner GT. Similar effects of atorvastatin, simvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001;85:47-51.
47. Armstrong M L. Regression of coronary atheromatosis in rhesus monkeys. Circ Res 1975; 36: 256.
48. Vesselinovith D. Reversal of advanced atherosclerosis in reshus monkeys. Light microscopic studies. Atherosclerosis 1976;23:155.
49. David AS. Regression of advanced atherosclerosis in swine. Arch Pathol Lab Med 1976; 100:372.
50. Helf G, Worthley SG, Fuster V, Fayad ZA, Zaman AG, Corti R, Fallon JT, Badimon JJ. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation 2002; 105:993-8.
51. Moreno PR, Lodder RA, Purusshothaman KR, Charash WE, Oconnor WN, Muller JE. Detection of lipid pool,thin fibrous cap,and inflamatory cells in human aortic atherosclerotic plaque by near-infrared spectroscpiy. Circulation 2002; 105:923-7.
52. Van de Pooll SW, Delsin DJ, Jukema JW et al. Raman spectroscopic investigation of atorvastatin, amlodipine, on atherosclerotic plaque development in ApoE3 Leiden transgenic mice. Atherosclerosis 2000; 164:65-71.
53. Nissen SE, Tuzcu EM, Soenhagen P et al. Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-80.
54. Cannon PC, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndroms. N Engl J Med 2004; 350:15.
55. Mitoni H, Egashira K, Kimura M. Fluvastatin has cholesterol-lowering independent "direct effects" on atherosclerotic vessels in high cholesterol diet-fed rabbits. Pharmacol Res 2003; 48:417-27.
56. Jorge PAR. Endotélio, lípides e aterosclerose. Arq Bras Cardiol 1997; 68: 129-34.